International Journal of Gynecological Cancer

Papers
(The TQCC of International Journal of Gynecological Cancer is 0. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-05-01 to 2026-05-01.)
ArticleCitations
Inguinofemoral lymphadenectomy technique in 10 steps387
The Asia-Pacific Gynecologic Oncology Trials Group (APGOT): building a Pan-Asian and Oceania women’s cancer research organization180
The Cukurova score in the prediction of primary cytoreduction in ovarian cancer136
Successful cervical cancer treatment during a monochorionic diamniotic twin pregnancy in a patient with history of preterm delivery97
Well-differentiated papillary mesothelial tumor of the peritoneum86
Complementary use of indocyanine green and technetium to enhance sentinel lymphadenectomy in vulvar cancer79
A population-based study of outcomes in adjuvant radiotherapy for stage II endometrial carcinoma60
Survey on implementation of molecular testing in ovarian cancer and PARP inhibitor: a national North-Eastern German Society of Gynecologic Oncology/Young Academy of Gynecologic Oncology/Arbeitsgemeins58
Surgical staging for locally-advanced cervical cancer: the answer remains ‘NO’57
Surgical technique and surgeon volume: the pursuit of data-driven outcomes57
Authors’ response to: “Methodological concerns regarding AGO score validation in low-grade ovarian cancers”56
O021/#374 Breast cancer patients are at increased risk of devoleping uterine serous cancer: implication for conseling – a seer analysis56
Best original research presented at the 25th European Congress on Gynaecological Oncology: best of ESGO 202456
Delivery of hereditary cancer genetics services to patients newly diagnosed with ovarian and endometrial cancers at three gynecologic oncology clinics in the USA, Brazil, and Mexico51
22nd meeting of the European Society of Gynaecological Oncology (ESGO 2021) report48
Utilization of artificial intelligence to mitigate health inequalities in gynecological cancer care46
CERVICAL MELANOMA WITH CEREBRAL DISSEMINATION: A DIAGNOSTIC AND THERAPEUTIC CHALLENGE IN GYNECOLOGIC ONCOLOGY45
HYPOFRACTIONATED RADIATION THERAPY WITH ADAPTIVE PLANNING FOR THE TREATMENT OF ENDOMETRIAL AND CERVICAL CANCER (HERA TRIAL)44
HIDDEN IN PLAIN SIGHT: DESMOPLASTIC SMALL ROUND CELL TUMOUR (DSRCT) PRESENTING AS A GYNAECOLOGICAL MALIGNANCY43
INTRA-OPERATIVE COMPLICATIONS OF GYNECOLOGIC ONCOLOGY SURGERIES IN A TEACHING HOSPITAL IN SUB-SAHARAN AFRICA: EXPERIENCE FROM ADDIS ABABA, ETHIOPIA43
COST-UTILITY ANALYSIS OF A MOLECULAR-INTEGRATED-PROFILE FOR WOMEN WITH (HIGH)INTERMEDIATE RISK ENDOMETRIAL CANCER - PORTEC-4A AN INTERNATIONAL, MULTICENTRE, RANDOMISED, PHASE 3 TRIAL43
LOWER LIMB LYMPHEDEMA AFTER TREATMENT OF CERVICAL CARCINOMA AND ITS IMPACT ON QUALITY OF LIFE42
SIGNIFICANCE & CLINICAL UTILITY OF 2-DEOXY-2-[18F] FLUORO-D-GLUCOSE-POSITRON EMISSION TOMOGRAPHY HIBRID IMAGING IN THE DIAGNOSIS & RESPONSE EVALUATION IN CERVIX CANCER.41
COLPOSCOPIC-HISTOLOGIC DIAGNOSTIC AGREEMENT IN CERVICAL INTRAEPITHELIAL NEOPLASIA 2+: A FIVE-YEAR REVIEW OF COLPOSCOPIC SERVICES AT THE NATIONAL HOSPITAL ABUJA, NIGERIA COLPOSCOPIC-HISTOLOGIC DIAGNOST41
A POTENTIAL BLIND SPOT FOR ANTIBODY–DRUG CONJUGATES TARGETING FOLATE RECEPTOR-140
THE LANDSCAPE OF VULVAR CANCER SURVIVAL AND TREATMENT CHARACTERISTICS IN BOTSWANA40
PEMBROLIZUMAB PLUS CHEMOTHERAPY WITH OR WITHOUT BEVACIZUMAB IN PARTICIPANTS WITH PERSISTENT, RECURRENT, OR METASTATIC CERVICAL CANCER: 5-YEAR FOLLOW-UP RESULTS FROM KEYNOTE-82637
Characteristics and real-world outcomes of patients with epithelial ovarian cancer who received niraparib plus bevacizumab first-line maintenance therapy in the COMB1NE study37
Use of social media for academic and professional purposes by gynecologic oncologists36
2022-RA-1127-ESGO The efficacy of MEK inhibitors in the treatment of low-grade serous ovarian cancers: a systematic review35
2022-RA-1495-ESGO Differential metabolism of estrogens in model cell lines and tissues of HGSOC subtypes35
2022-RA-1001-ESGO Analysis of postoperative wound infections in malignancies of the female internal tract34
2022-RA-981-ESGO Can misdiagnosis be avoided in case of intestinal-type carcinoma of the vagina?A literature comprehensive review33
2022-RA-828-ESGO A case of 19 years old, female with malignant spindle cell neoplasm; pelvic monophasic synovial sarcoma arising from the pelvic ligaments33
2022-RA-630-ESGO Overexpression of PDEA1 is a predictive biomarker for platinum resistance and poor prognosis in epithelial ovarian cancer by regulating cell cycle32
2022-RA-684-ESGO Factors affecting survival outcomes of patients with clear cell endometrial carcinoma30
2022-RA-991-ESGO Assessment of high-risk human papillomavirus infections and cervical dysplasia in human immunodeficiency virus-positive pregnant women in germany: a prospective cross-sectional two-ce30
2022-RA-1318-ESGO Immunohistochemical profiling of macrophage subtypes in the microenvironment of ovarian tumours in young women30
2022-RA-1690-ESGO Rare uterine cervical adenocarcinomas in salah azaiez institute: clinicopathological features30
2022-RA-1194-ESGO Efficacy of dostarlimab in endometrial cancer by molecular subtype: a post hoc analysis of the GARNET study29
2022-RA-1187-ESGO Management and outcomes in high risk GTN – a regional cancer center experience29
2022-RA-1387-ESGO Patients with minimal residual disease at upfront debulking surgery have similar survival outcome than patients with complete cytorreduction after neoadjuvant chemotherapy28
2022-RA-1427-ESGO Fertility outcomes following radical trachelectomy for cervical cancer – a single centre ten year retrospective cohort study28
2022-RA-1019-ESGO Endometrial hyperplasia and cancer: results of two reference hospitals in Ankara28
2022-RA-1223-ESGO Cervical cancer in pregnancy: what are the challenges?28
2022-RA-1272-ESGO Cost-effectiveness of risk-reducing surgery for breast and ovarian cancer prevention: a systematic review27
2022-LBA-414-ESGO Preliminary clinical outcome of ADP-A2M4CD8, a next-generation autologous T-cell receptor T-cell therapy, in patients with advanced epithelial ovarian cancer27
2022-RA-421-ESGO DeflaGyn® has cytotoxic, genotoxic and apoptotic effects on human adenocancer cells: an in vitro study27
2022-RA-1191-ESGO Efficacy of a multi-ingredient coriolus versicolor-based vaginal gel in high-risk HPV women over 40: sub-analysis of the paloma clinical trial & papilobs real-life study27
2022-RA-1604-ESGO Efficiency of simulation program for OB/GYN residents using self-training and supervised sessions: a quantitative study27
2022-RA-1245-ESGO Correlation between false negatives of FDG-TEP staging in locally advanced cervical cancer and FIGO 2009 clinical staging system. A retrospective single-center cohort26
Hepatic hilum cytoreductive surgery for ovarian cancer relapse☆26
2022-RA-1635-ESGO Accuracy of MRI imaging in preoperative stage assessment of endometrial cancer in determining extension of surgical procedure26
Three-dimensional image of uterine transposition26
2022-RA-1171-ESGO Total vaginectomy for recurrent gynecological cancer. Experience in kazior26
Response to the letter regarding the article “Predictive factors for adnexal involvement in endometrial cancer FIGO stage IIIA”26
Primary ovarian leiomyosarcoma: results from an analysis by the French Sarcoma Group (Ovarian SArcoma MAnagement – OSAMA Study)25
Growing teratoma syndrome25
Vulvar cancer resection with V–Y advancement flap reconstruction25
Correspondence on “Immune checkpoint inhibitor combinations for patients with advanced endometrial cancer: a network meta-analysis and cost-utility analysis” by Zhu and colleagues24
Evaluating the use of machine learning in endometrial cancer: a systematic review24
Use of quadratus lumborum block in gynecologic procedures24
Safety and management of niraparib monotherapy in ovarian cancer clinical trials24
PARSGO and UM6SS: spearheading excellence in gynecological oncology in Morocco24
Updates and controversies in the management of uterine serous carcinoma and uterine carcinosarcoma24
Pocket guide based on the TNM and FIGO staging systems for classifying patients with locally advanced cervical cancer: a practical tool from the GINECO group for quick and easy management23
Erratum to ‘Controversies in vulvar cancer: revisiting the margin of error’ [International Journal of Gynecological Cancer Volume 35 Issue 3 (2025) 101678]23
Correction: SUCCOR quality: validation of ESGO quality indicators for surgical treatment of cervical cancer23
Management of intravenous leiomyomatosis: a comprehensive review of surgical and perioperative considerations22
Controversies in the management of mucinous ovarian tumors22
Letter in response to correspondence on “Comparative analysis of adjuvant treatment outcomes in stage III endometrial cancer: overall survival, recurrence-free survival, site of primary recurrence, an22
Role of pre-diagnostic reproductive factors on long-term (10 years or greater) survival of epithelial ovarian cancer: The Extreme study22
Response to the Correspondence by Xu et al. on “Diagnostic performance of ultrasound-guided biopsy for detecting recurrent or persistent cervical cancer after chemoradiotherapy: a prospective, single-22
Real-world data from the oncosys-OVA clinical trial (NCT06117384) - experiences on genomic and functional HRD testing and molecular determinants of progression during PARP inhibitor treatment21
Epigenetic mechanisms of parpi resistance in ovarian cancer: A systematic review with bioinformatic analysis of clinically actionable genes21
Distribution of molecular subgroups in advanced-stage endometrial cancer: A unicentric retrospective cohort study21
Ovarian reserve in young BRCA mutation carriers: a case-control analysis in reproductive-age women21
Performance of a generative AI model in assigning FIGO 2023 endometrial cancer stages compared with clinician assessment21
Prognostic impact of low-volume metastatic disease in sentinel lymph nodes of patients with early-stage squamous cell carcinoma of the vulva21
New gynaecological cancer diagnoses in women with a history of breast cancer21
Step-by-step type C1 robotic radical histerectomy20
Open label, multicenter, phase 2 study of farletuzumab ecteribulin, a folate receptor alpha-targeting antibody-drug conjugate, alone and in combination with lenvatinib in platinum-resistant ovarian ca20
Association between BRCA1/2 mutation and chemotherapy response score in high grade advanced ovarian cancer: a retrospective cohort study20
Safety of advanced laparoscopic procedures in gynaecologic oncology: a single-centre prospective cohort study20
Mucinous ovarian cancer: A tertiary care centre experience over 10 years20
Impact of controlled ovarian stimulation and oocyte cryopreservation on recurrence and reproductive rates in patients with borderline or malignant ovarian tumours: a retrospective study from a single 20
Daphnetin enhances cisplatin chemosensitivity in ovarian cancer by triggering proinflammatory macrophage polarization.20
Head-to-head comparison between multidisciplinary team and artificial intelligence decision-making in advanced ovarian cancer and predictive accuracy of surgical complexity score: a pragmatic study20
Ovarian cancer diagnosis within 28 days after an emergency admission to hospital: a national population-based study of patient risk factors and cancer characteristics using routinely collected data in19
Re-irradiation with stereotactic radiotherapy for positive and close margins after pelvic exenteration for recurrent gynaecological cancer19
Favouring upfront surgery in primary peritoneal cancer: survival impact beyond histology19
Awareness of HPV and HPV vaccination in the primary care: A nationwide cross-sectional study19
Evolution of germline and somatic genetic testing in high-grade serous tubo-ovarian carcinoma: A single-centre experience in the czech republic from 2015–202319
Molecular profiling and clinicopathological characteristics of endometrial carcinoma in the kazakh population: first national cohort study (BR24992933)19
Implementation of enhanced recovery after surgery (ERAS) principles in gynecologic oncology: A multi-institutional evaluation from greece18
A minimally invasive treatment approach for early-stage uterine cervical cancer: the impact of the LACC trial18
Evaluating the feasibility of large language models in gynecologic oncology decision-making: A comparative study of chatGPT, google gemini, and bing copilot18
The dark side of endometriosis: exploring different atypical and neoplastic transformations18
Efficacy and safety of dostarlimab plus carboplatin–paclitaxel in first line patients with mismatch repair deficient or microsatellite instability-high recurrent or primary advanced endometrial cancer18
Preoperative risk stratification of p53-abnormal endometrial cancer using expert ultrasound: clinical relevance of nodal staging in a multicentre retrospective study18
Clinicopathologic factors associated with recurrence in immature ovarian teratoma: A retrospective institutional study18
PREVALENCE PATTERN OF HIGH-RISK HUMAN PAPILLOMAVIRUS GENOTYPES IN WOMEN WITH CERVICAL INTRAEPITHELIAL LESIONS IN NORTH MACEDONI18
Optimizing sentinel lymph node detection in early-stage ovarian cancer: indocyanine green alone or combined with technetium-99m?17
Survival impact of histological response to neoadjuvant chemotherapy according to number of cycles in patients with advanced ovarian cancer17
Sarcopenia shortens overall survival of patients with platinum-resistant recurrent ovarian cancer: inverse probability of treatment-weighting analysis17
Impact of the COVID-19 pandemic on service recovery and referral pathways in endometrial cancer care17
Efficacy of a multi-ingredient coriolus versicolor-based vaginal gel on HR-HPV clearance: final results from the PALOMA 2 clinical trial17
To Compare The Colposcopic Findings By International Federation Of Colposcopy And Cervical Pathology (IFCPC ) Nomenclature And Swede Score For Assessment Of High Grade Cervical Lesions17
Acceptability of the EORTC-CX24 quality of life questionnaire in a portuguese sample of cervical cancer treated patients17
Clinical and prognostic impact of the MELF pattern of invasion in endometrioid endometrial carcinoma: A retrospective multivariable evaluation of histopathologic and molecular correlates17
Patterns of care and development of quality indicators in patients with non-epithelial and rare ovarian tumors in Australia: insights from the National Gynae-Oncology Registry17
Spectrum of molecular subtypes and their clinical associations in endometrial carcinoma: A cohort analysis17
A Multivariable Prognostic Analysis For Survival Outcomes In Women With Epithelial Ovarian Cancer - A North Indian Single Centre Study16
Secondary Debulking Followed By Localised Radiotherapy In Patients With Oligometastatic Recurrent Ovarian Cancer – A Case Series Of Two International Cancer Centres16
Prospective Multicentre Evaluation Of Secondary Cytoreductive Surgery In The Era Of PARP-Inhibitors (CONCEPT) In Relapsed Epithelial Ovarian Cancer16
Evaluating The Implementation And Outcomes Of The Tumor-First Testing Strategy For BRCA1/2 Pathogenic Variants In Ovarian Cancer Patients: A Center-Wide Analysis16
SPLEEN PRESERVING EXTENSIVE CYTOREDUCTIVE SURGERY16
Does The Origin Of Ovarian Cancer Influence Outcomes?16
The Role Of Prehabilitation In ERAS For Gynecologic Oncology In Germany16
Prognostic Factors In Adult Granulosa Cell Tumours Of The Ovary And Long Term Follow-Up. (The Norwegian Radium Hospital Experience 1971-2024)16
The Silva Pattern-Based Classification And Oncological Outcomes In Women Undergoing Fertility-Sparing Surgery For Early-Stage Cervical Cancer16
Trop-2 Expression In Cervical Carcinoma (CX) - A Possible Target For The Antibody Drug Conjugate Sacituzumab15
Assessment Of The Predictive Role Of Khorana Score And Genomic Profiling In Ovarian Cancer-Related Venous Thromboembolism15
Surgical Release Of The Pudendal Nerve By Robotic Approach In 10 Steps15
Perioperative Outcomes Of Heated Intraperitoneal Chemotherapy For Patients Enrolled In The Feasibility Phase Of A Randomized Controlled Trial: Laparoscopic Cytoreduction After Neoadjuvant Chemotherapy15
Histological Findings After Completion Hysterectomy And Clinical Outcome Following Conservative Treatment Of Endometrial Carcinoma15
Patient-initiated follow-up in low-risk endometrial cancer after surgery: a systematic review14
Homologous Recombination Deficiency (HRD) In P53 Abnormal Endometrial Carcinoma14
Excision Of Retroperitoneal Mass - Laparoscopic Management Of Iliac Artery Injury14
Survival Prediction And Mortality Risk Stratification In Ovarian Cancer After NACT: PRGS Outperforms CRS Regression Scoring14
The Prognostic And Predictive Value Of Cardiophrenic Lymph Nodes In Patients Receiving Hyperthermic Intraperitoneal Chemotherapy For Ovarian Cancer In The OVHIPEC-1 Trial14
Impact Of Surgery On Survival Outcomes In Locally Advanced Cervical Cancer Patients With Partial Response After Primary Chemoradiotherapy14
Impact Of Preoperative Conization On The Prognosis Of Cervical Cancer Patients Undergoing Open Abdominal Radical Hysterectomy14
Comparative Outcomes Of Excision And Active Surveillance For Cervical Intraepithelial Neoplasia 2 In Women Under 3513
Computed tomography–based prediction of interval cytoreduction in advanced ovarian cancer13
ATOMICC trial: a randomized, open-label, phase II trial of anti-PD1, dostarlimab, as maintenance therapy for patients with high-risk locally advanced cervical cancer after chemoradiation13
Impact Of Ascites And Peritoneal Metastatic Lesion Volumes, Measured By Newly Developed Deep Learning-Based Algorithm, In Advanced Epithelial Ovarian Cancer13
A Young Woman Presenting Virilization With Ovarian Mass: A Case Report Of Rare Disease - Ovarian Steroid Tumor13
The Role Of Second-Look Surgery In Recurrent Ovarian Cancer Based On The Type Of Relapse13
Clinical Significance Of Low Volume Lymph Node Metastasis In Early Stage Cervical Cancer: A Single Centre Case Series13
Epithelial ovarian cancer and borderline tumors during pregnancy: a report from the International Network on Cancer, Infertility, and Pregnancy13
Advanced Techniques In Pelvic Exenteration For Cervical Cancer: A Case-Based Surgical Guide13
PROGNOSTIC FACTORS BASED ON THE MOLECULAR CLASSIFICATION OF ENDOMETRIAL CANCER: SINGLE INSTITUTION STUDY13
Surgical Treatment Of Advanced Ovarian Cancer: Experience From A Brazilian Cancer Center (Barretos Cancer Hospital) In 202313
Does Sentinel Node Know The Cancer Origin? Comparing Sentinel Lymph Nodes Localization In Endometrial And Cervical Cancer13
Squamous Cell Carcinoma Arising In Mature Cystic Teratomas: A Case Series Review Of Presentation, Treatment, And Prognosis13
Role of minimally invasive secondary cytoreduction in patients with recurrent ovarian cancer13
A fully next-generation sequencing-based method of classifying molecular sub-types of endometrial cancer retains prognostic value and expands biomarker targets13
The “N-PLUS/NOGGO-Ov53/ENGOT-Ov62-STUDY” To De-Escalate Chemotherapy In Ovarian Cancer: Comparing 3 Vs. 6 Cycles Of Platinum-Based Chemotherapy After Complete Tumor Resection Followed By Niraparib Mai13
Early-Stage Breast Cancer: A Detailed Examination Of Clinicopathological Features13
Performance of molecular classification in predicting oncologic outcomes of fertility-sparing treatment for atypical endometrial hyperplasia and endometrial cancer12
Improvement in radiation techniques for locally advanced cervical cancer during the last two decades12
ROCC/GOG-3043: a randomized controlled trial of robotic versus open surgery for early-stage cervical cancer12
Addition of metronidazole to standard-of-care perioperative prophylaxis at the time of hysterectomy for gynecologic malignancies12
Can the Tilburg Frailty Indicator predict post-operative quality of recovery in patients with gynecologic cancer? A prospective cohort study12
Pelvic lymph node decidua mimicking metastatic cervical cancer in pregnancy12
Journal Information12
Correspondence on “Comparison of the efficacy and safety of five-day methotrexate versus pulse actinomycin D for low-risk gestational trophoblastic neoplasia: a single-center historical cohort study” 12
Clinical and pathological overview of endometrial endometrioid carcinoma12
Neoadjuvant chemotherapy with interval debulking surgery in elderly women with advanced ovarian, fallopian tube, or primary peritoneal cancer: real-world evidence from japan12
Surgical modality non-inferiority testing with an intensification of adjuvant treatments: a missed opportunity12
A randomized phase II trial to examine modified vaccinia Ankara-5T4 vaccine in patients with relapsed asymptomatic ovarian cancer (TRIOC)12
Transfusion use and effect on progression-free, overall survival, and quality of life in upfront treatment of advanced epithelial ovarian cancer: evaluation of the European Organization for Research a12
Robot-assisted utero-ovarian transposition and reanastomosis in vaginal cancer: a step-by-step description technique12
OPTIMIZING RADIATION THERAPY DELIVERY IN POST-HYSTERECTOMY PROLAPSE: A CASE FOR VAGINAL PESSARY USE11
SELECTIVE INTRAOPERATIVE BIOPSY IN ENDOMETRIAL ATYPIA: DEVELOPMENT AND VALIDATION OF A 55/20 RISK SCORE WITH 10-YEAR DIAGNOSTIC AND ECONOMIC OUTCOMES IN CHILE11
THE MANAGEMENT OF BREAST MELANOMA: EXPERIENCE OF A SINGLE INSTITUTE11
Mirvetuximab soravtansine shines post-PARP inhibitor progression: promising insights from the PICCOLO trial11
Proof-of-concept randomized phase II non-inferiority trial of simple versus type B2 hysterectomy in early-stage cervical cancer ≤2 cm (LESSER)11
Long-term impact of surgical route and tumor size on risk of recurrence among early-stage cervical cancer patients in a managed care population11
CERVICAL CANCER IN ZIMBABWEAN WOMEN IN THE AWACAN-ED STUDY: EVALUATING THE CLINICO-PATHOLOGICAL CHARACTERISTICS SND FACTORS INFLUENCING STAGE AT PRESENTATION IN WLWH COMPARED TO HIV UNINFECTED WOMEN11
TRIAL-IN-PROGRESS: A PHASE II INTERVENTIONAL STUDY OF HPV L1 VACCINE IN COMBINATION WITH IMIQUIMOD AND METFORMIN IN GYNECOLOGIC SQUAMOUS CANCERS11
UPDATES ON THE INTERNATIONAL GYNECOLOGIC CANCER SOCIETY (IGCS) GLOBAL FELLOWSHIP PROGRAM11
A RCT COMPARING THE USE OF LIGNOCAINE SPRAY AND PARACERVICAL BLOCK FOR PAIN RELIEF PRIOR TO LLETZ11
Treatment tolerability associated with carboplatin dose based on actual versus adjusted body weight in patients with a body mass index ≥25 kg/m2 with advanced ovarian cancer11
MULTIMODAL PREOPERATIVE OPTIMIZATION IN HIGH-COMPLEXITY GYNECOLOGIC ONCOLOGY SURGERIES: PERSPECTIVES AND OUTCOMES11
The impact of BRCA status on the efficacy of paclitaxel monotherapy in recurrent ovarian cancer11
Advanced ovarian yolk sac tumor: upfront surgery or neoadjuvant chemotherapy followed by interval debulking?11
A RETROSPECTIVE STUDY OF LYMPHADENECTOMY IN PATIENTS WITH ADVANCED OVARIAN CLEAR CELL CARCINOMA11
Incidence And Impact Of Low Volume Lymph Node Metastasis In Apparent Early-Stage Ovarian Cancer – MICR-OVARY Study.11
EPIDEMIOLOGICAL PROFILE OF MICROINVASIVE DUCTAL CARCINOMA OF THE BREAST11
PATTERNS AND OUTCOMES OF PALLIATIVE RADIOTHERAPY IN ADVANCED VULVAR CANCER IN A HIGH HIV-PREVALENCE SETTING11
COMPREHENSIVE MOLECULAR CHARACTERIZATION OF OVARIAN CANCER: INTEGRATED ANALYSIS OF GENOMIC, HORMONAL, AND IMMUNOLOGIC BIOMARKERS ACROSS TUMOR GRADES AND SUBTYPES11
Fertility-sparing treatment in early-stage cervical adenocarcinoma: assessing feasibility and limitations11
REAL-WORLD TREATMENT PATTERNS AND OUTCOMES IN PATIENTS DIAGNOSED WITH ADVANCED ENDOMETRIAL CANCER TREATED WITH IMMUNO-ONCOLOGY THERAPIES IN THE UNITED STATES: 2019-202411
Racial and sociodemographic disparities in the use of targeted therapies in advanced ovarian cancer patients with Medicare11
Journal Information11
O024/#1151 Trends in clinical trial accrual of underrepresented patients with gynecologic malignancy11
HIGH RISK GESTATIONAL TROPHOBLASTIC NEOPLASIA IN A MIDDLE – INCOME SETTING: A RETROSPECTIVE REVIEW OF MANAGEMENT AND OUTCOMES IN A SINGLE TERTIARY INSTITUTION IN SOUTH AFRICA.11
2022-RA-1470-ESGO Is neoadjuvant chemotherapy effective as prehabilitation program in advanced epithelial ovarian cancer?10
2022-VA-1166-ESGO Suspicious lymph nodes in advanced ovarian cancer: debulking surgery10
The tug of war: delivering safe gynecologic oncology treatment amid insecurity in Haiti10
Rare intra-tumoral colonization of Fusobacterium nucleatum in endometrial cancer10
Correspondence on “Complications of HIPEC for ovarian cancer surgery: evaluation over two time periods” by Navarro Santana et al10
2022-RA-711-ESGO Association of PET-CT tumor metabolic metrics and intraepithelial and stromal tumor-infiltrating lymphocytes in locally advanced cervical cancer prior to concurrent chemo-radiotherapy10
2022-RA-1540-ESGO MITO 25.1: a randomized, molecular driven phase II trial of carboplatin-paclitaxel-bevacizumab vs carboplatin-paclitaxel-bevacizumab-rucaparib vs carboplatin-paclitaxel-rucaparib, se10
2022-RA-1518-ESGO Role of Plastic surgery following resection of vulval tumours: Is collaboration the key?10
2022-RA-1114-ESGO BRCA I, BRCA II mutation in high grade ovarian cancers, fallopian tube cancer, primary peritoneal carcinoma10
Rising endometrial cancer rates and potential for screening10
PRIMARY RECTAL MUCINOUS ADENOCARCINOMA METASTASIS TO THE BREAST IN AN 18-YEAR OLD FEMALE : A CASE REPORT10
2022-RA-744-ESGO Hepatitis B screening to reduce the risk of viral reactivation in gynecologic oncology patients receiving chemotherapy at a regional tertiary cancer centre: a quality improvement init10
Advanced metastatic G1 endometrioid endometrial carcinoma (no specific molecular profile group)10
2022-RA-173-ESGO Endometrioid borderline ovarian tumor: clinical characteristics, prognosis and management10
2022-RA-1180-ESGO Nonfunctional complications associated with radical hysterectomy10
2022-VA-739-ESGO Pelvic sentinel lymph node dissection in endometrial cancer10
Opioid and benzodiazepine use in gynecologic oncology patients10
Expanding the workforce of clinical trial investigators committed to gynecologic cancer research: the GOG Foundation, Inc’s Scholar Career Development Award and New Investigator Program10
Peritoneal cancer index: laparoscopic evaluation of peritoneal carcinomatosis from gynecological origin10
Correspondence on ‘Molecular profile is a strong predictor of the pattern of recurrence in patients with endometrial cancer’ by Luzarraga Aznar et al10
2022-RA-753-ESGO Is laparoscopy a safe approach for treatment of stage II endometrial cancer? A single centre 10 years experience10
2022-RA-1648-ESGO Cardiophrenic lymph node involvement for ovarian cancer10
2022-RA-816-ESGO The impact of the new RCOG 2019 curriculum and COVID 19 pandemic on gynaecological training amongst the specialist trainees in the United Kingdom: a prospective study9
2022-RA-719-ESGO Impact of COVID-19 on radical (chemo)radiotherapy for locally advanced cervical cancer in the West of Scotland, April 2020 – March 20219
2022-RA-1423-ESGO Phyllodes tumors of the breast analysis of 17 patients9
First workshop on cervix cancer surgery in Latin America: a hands-on experience from Lima, Perú9
Assessing ovarian cancer via laparoscopic video: inter-rater and intra-rater reliability9
2022-RA-605-ESGO Long term quality of life after chemotherapy among rare ovarian cancer survivors: the national gineco case-control Vivrovaire Rare Tumors study9
2022-VA-1642-ESGO Tricks to improve the laparoscopic extraperitoneal space in para-aortic lymphadenectomy9
2022-RA-1128-ESGO Has endometrial cancer treatment changed during the last years? A cancer registry data-based approach to monitor expected treatment changes after the release of the corresponding S3 9
2022-RA-1009-ESGO Immune-related endpoints in patients with advanced or recurrent endometrial cancer treated with dostarlimab in the GARNET study9
2022-RA-845-ESGO Laparoscopic sentinel lymph node mapping in endometrial cancer: A retrospective single center observational study9
2022-RA-806-ESGO Implication of FDG-PET/CT parameters for predicting prognosis of high grade neuroendocrine cervical cancer patient9
Prognostic impact of para-aortic surgical staging in stage IIIC1 cervical cancer according to the FIGO 2018 classification9
2022-RA-1576-ESGO Deep-learning-based endometrial segmentation and automated immune profiling from histopathological whole slide images9
2022-RA-733-ESGO Duration of HPV persistence and its relationship with recurrent cervical dysplasia9
2022-RA-1488-ESGO Long-term effects of premenopausal risk-reducing salpingo-oophorectomy on cognition in women with high familial risk of ovarian cancer9
2022-LBA-1708-ESGO Will centralization of ovarian cancer treatment be beneficial in Poland ?9
2022-RA-1659-ESGO Oncological outcomes of unexpected uterine leiomyosarcomas: a single centre retrospective analysis9
2022-RA-1631-ESGO ABC of surgical teaching: time to consider a global blueprint for holistic education9
2022-RA-945-ESGO Antitumour activity of dostarlimab by PD-L1 and tumour mutation burden in patients with mismatch repair deficient and proficient tumours in the GARNET trial9
Correspondence on “Use and outcomes of hormonal therapy for advanced stage, low-grade serous ovarian cancer” by Yoh et al9
2022-RA-1562-ESGO Primary ovarian large B cell lymphoma: About six rare cases9
2022-RA-1289-ESGO Understanding clinical and pathological heterogeneity of endometrial cancer with no specific molecular profile (NSMP)9
Breast cancer risk after ovarian cancer in patients with BRCA mutations: Implications in an era of improving survival8
Correspondence on “Long-term oral contraceptive use as a risk factor for high-grade cervical lesions in women with high-risk human papillomavirus: a retrospective cohort analysis” by Farzaneh et al8
The use of vacuum packing for specimen preservation within gynae-oncology8
Preoperative circulating cell-free DNA as predictor of postoperative complications after primary and interval cytoreductive surgery for advanced ovarian cancer8
HALP index (hemoglobin, albumin, lymphocytes, platelets) as an independent prognostic factor in locally advanced cervical cancer.8
PARP inhibitor maintenance therapy with niraparib in patients with primary advanced or recurrent endometrial cancer receiving dostarlimab plus chemotherapy8
Oncologic outcomes of surgical para-aortic lymph node staging in patients with advanced cervical carcinoma undergoing chemoradiation8
Should lymph node staging be tailored according to molecular profile in endometrial cancer?8
Preliminary outcomes of a nurse-led digital chatbot for women with suspected gynaecologic cancer: improving anxiety, satisfaction, and care continuity8
Prognostic role of PIK3CA gene mutations in early-stage endometrial carcinoma in the context of the 2023 FIGO classification8
From avoiding empty packets to real-time diagnosis: the value of robotic ultrasound-guided surgery in sentinel lymph node dissection8
Oncological outcomes after laparotomic, laparoscopic, and robot-assisted laparoscopic staging for early high–intermediate or high-risk endometrial cancer8
Fertility-sparing approach for uterine smooth muscle tumors of uncertain malignant potential8
Paraneoplastic cerebellar degeneration with anti-yo antibodies in serous ovarian carcinoma: A case report and literature review8
Characterization of B cell activation and spatial distribution in the tumor microenvironment of high-grade serous ovarian cancer8
Primary cytoreduction compared to neoadjuvant chemotherapy followed by interval cytoreductive surgery for advanced ovarian cancer: retrospective study8
Immune and endocrine paraneoplastic manifestations in adolescent ovarian tumors: A comparative observational study8
0.34706592559814